Development of clinical assay to mitigate daratumumab, an IgG1κ monoclonal antibody, interference with serum immunofixation (IFE) and clinical assessment of M-protein response in multiple myeloma

被引：17
|
作者：
Axel, Amy E. [1 ]
McCudden, Christopher R. [2 ]
Xie, Hong [1 ]
Hall, Brett M. [1 ]
Sasser, A. Kate [1 ]
机构：
[1] Janssen R&D, Spring House, PA USA
[2] Ottawa Hosp, Ottawa, ON, Canada
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-2563
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2563
引用
下载
收藏
页数：1
相关论文
共 17 条
  • [1] Assessing clinical response in multiple myeloma (MM) patients treated with monoclonal antibodies (mAbs): Validation of a daratumumab IFE reflex assay (DIRA) to distinguish malignant M-protein from therapeutic antibody.
    McCudden, Christopher
    Axel, Amy
    Slaets, Dominique
    Frans, Sandy
    Bald, Jaime
    Schecter, Jordan Mark
    Ahmadi, Tahamtan
    Plesner, Torben
    Sasser, Kate
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA)
    van de Donk, Niels W. C. J.
    Otten, Henny G.
    El Haddad, Omar
    Axel, Amy
    Sasser, A. Kate
    Croockewit, Sandra
    Jacobs, Joannes F. M.
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2016, 54 (06) : 1105 - 1109
  • [3] Isatuximab-Specific Immunofixation Electrophoresis Assay to Remove Interference in Serum M-Protein Measurement in Patients with Multiple Myeloma
    Thoren, Katie
    Menad, Samia
    Nouadje, Georges
    Mace, Sandrine
    JOURNAL OF APPLIED LABORATORY MEDICINE, 2024, : 661 - 671
  • [4] Isatuximab-Specific Immunofixation Electrophoresis Assay to Remove Interference in Serum M-Protein Measurement in Patients with Multiple Myeloma
    Thoren, Katie
    Menad, Samia
    Nouadje, Georges
    Mace, Sandrine
    JOURNAL OF APPLIED LABORATORY MEDICINE, 2024, 9 (04): : 661 - 671
  • [5] Impact of M-protein detection on the response evaluations of patients undergoing treatment with the IgG-κ monoclonal antibodies daratumumab or isatuximab, and discrepancies between immunofixation electrophoresis (IFE) systems and reagents
    Shirouchi, Yuko
    Kaihara, Kazumi
    Sekita, Tsunaki
    Amano, Naoko
    Nakayama, Konosuke
    Miyake, Kazunori
    Abe, Hitoshi
    Oinuma, Hirotoshi
    Maruyama, Dai
    CANCER MEDICINE, 2024, 13 (16):
  • [6] Development of a Hydrashift 2/4 Isatuximab Assay to Mitigate Interference with Monoclonal Protein Detection on Immunofixation Electrophoresis in Vitro Diagnostic Tests in Multiple Myeloma
    Finn, Greg
    Mace, Sandrine
    Chu, Ruiyin
    van de Velde, Helgi
    Menad, Samia
    Melki, Marie-Therese
    Nouadje, Georges
    BLOOD, 2020, 136
  • [7] QT Interval Effects and M-Protein Response in a Phase 1 Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) in Patients with Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma
    Thomas, Sheeba K.
    Suvorov, Alexander
    Noens, Lucien
    Rukavitsin, Oleg
    Fay, Joseph
    Wu, Ka Lung
    Zimmerman, Todd M.
    van de Velde, Helgi
    Bandekar, Rajesh
    Puchalski, Thomas A.
    Qi, Ming
    Uhlar, Clarissa
    Samoilova, Olga S.
    BLOOD, 2012, 120 (21)
  • [8] Development of a Microflow Digital Imaging Assay to Characterize Protein Particulates During Storage of a High Concentration IgG1 Monoclonal Antibody Formulation
    Wuchner, Klaus
    Buchler, Jochen
    Spycher, Rene
    Dalmonte, Paul
    Volkin, David B.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2010, 99 (08) : 3343 - 3361
  • [9] Simulation of Clinical Endpoints (Survival, PFS) in Patients With Refractory Multiple Myeloma Treated With Pomalidomide Based on Interim Week 8 M-protein Response
    Bruno, R.
    Jonsson, F.
    Zaki, M.
    Jacques, C.
    Richardson, P.
    Rajkumar, V. S.
    Claret, L.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S647 - S647
  • [10] Incidence and clinical characteristics of multiple myeloma with low M-protein levels and normal values of hemoglobin, creatinine, calcium, and serum free light chain ratio
    Szabo, Agoston Gyula
    Klausen, Tobias Wirenfeldt
    Abildgaard, Niels
    Gregersen, Henrik
    Silkjaer, Trine
    Pedersen, Per Trollund
    Pedersen, Robert Schou
    Helleberg, Carsten
    Hermansen, Emil
    Schnack, Brian Iversen
    Vangsted, Annette Juul
    BLOOD CANCER JOURNAL, 2021, 11 (04)
12